Anavex Life Sciences Corp. 面临证券欺诈的集体诉讼
Anavex Life Sciences Corp. 正面临一起证券欺诈的集体诉讼，这起诉讼是在其首席执行官被解雇以及披露内部控制存在重大缺陷之后引发的。
为什么重要. Anavex 的投资者可能会受到诉讼的影响，这可能会影响公司的股价和运营。
01
证据
- PPR Newswire news releases公司披露2026-10-08 22:00
that there was a material weakness in internal control over financial reporting that existed at September 30, 2025
- PPR Newswire news releases公司披露2026-10-08 22:00
Anavex's stock price fell $0.22 per share, or 6.59%, to clos at $3.12 per share on May 7, 2026.
- PPR Newswire news releases公司披露2026-10-08 22:00
On this news, Anavex's stock price fell $0.19 per share, or 6.35%, to close at $2.80 per share on August 31, 2026
- PPR Newswire news releases公司披露2026-10-08 22:00
the Company's disclosure controls and procedures were not effective as of September 30, 2025
- PPR Newswire news releases公司披露2026-10-08 22:00
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Anavex Life Sciences Corp.
- PPR Newswire news releases公司披露2026-10-08 22:00
Then, on August 28, 2026, Anavex filed with the SEC an amended Annual Report on Form 10-K/A for the fiscal year ended September 30, 2025 (the "Amended 2025 Annual Report"), which disclosed management's conclusion "that there was a material weakness in internal control over finan…